Pronova touts blockbuster, prepares IPO

Touting what it terms as a potential blockbuster among its products, Norway's Pronova BioPharma has outlined plans to sell about 106 million shares in an IPO prices at 23-29 nkr a share. The IPO for Pronova, which develops drugs based on Omega-3 fish oil, values the company at $1.25 billion to $1.57 billion.

"Pronova BioPharma is a highly profitable, fast-growing biopharma company and following strong progress in recent years, it is now an appropriate time to broaden our shareholder base," said Pronova chief executive Tomas Settevik.

- read the AFX report on Pronova's plans

ALSO: Targanta Therapeutics expects to raise up to $67.9 million from its IPO. Targanta was a 2007 Fierce 15 company. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.